Compare MAN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | XNCR |
|---|---|---|
| Founded | 1948 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 1994 | 2013 |
| Metric | MAN | XNCR |
|---|---|---|
| Price | $46.07 | $38.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $51.94 | $42.50 |
| AVG Volume (30 Days) | 911.0K | ★ 1.6M |
| Earning Date | 10-15-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $17,957,100,000.00 | $125,576,000.00 |
| Revenue This Year | $6.51 | $57.39 |
| Revenue Next Year | $3.29 | N/A |
| P/E Ratio | $24.28 | ★ N/A |
| Revenue Growth | 0.58 | ★ 13.65 |
| 52 Week Low | $25.15 | $10.38 |
| 52 Week High | $63.88 | $40.60 |
| Indicator | MAN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 74.05 |
| Support Level | $25.57 | $11.05 |
| Resistance Level | $48.48 | N/A |
| Average True Range (ATR) | 1.67 | 2.30 |
| MACD | 0.40 | 0.98 |
| Stochastic Oscillator | 47.54 | 82.63 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.